This is a working overview of Selank, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-27. Anything still debated is marked as such rather than presented as settled.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
| Property | Value | Notes |
|---|---|---|
| Identity confirmation | Reversed-phase HPLC retention time versus reference standard | Retention depends on column, gradient, and ion-pairing agent |
| Mass confirmation | Electrospray or MALDI mass spectrometry | Doubly protonated ion near m/z 377 is consistent with about 752 Da |
| Typical purity specification | 95 percent or higher by chromatographic peak area | Lower values suggest truncated or modified peptide species |
| Storage of lyophilized powder | -20 °C, desiccated, protected from light | Powder tolerates long storage better than solution |
| Storage of solution | 2-8 °C for short periods | Freeze-thaw cycling promotes aggregation and surface adsorption |
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Biochemistry is the study of the chemicals, chemical reactions and interactions that occur in living organisms. Biochemistry is highly interdisciplinary, covering medicinal chemistry, neurochemistry, molecular biology, forensics, plant science and genetics. Neurochemistry is the study of neurochemicals; including transmitters, peptides, proteins, lipids, sugars, and nucleic acids; their interactions, and the roles they play in forming, maintaining, and modifying the nervous system. Inorganic chemistry traditionally was the study of metals and minerals, but is mainly concerned with the structure and behavior of compounds derived from metals and main group elements. The distinction between organic and inorganic disciplines is not absolute and there is much overlap, most importantly in the sub-discipline of organometallic chemistry. Materials chemistry is the preparation, characterization, and understanding of solid state components or devices with a useful current or future function. The field is a new breadth of study in graduate programs, and it integrates elements from all classical areas of chemistry like organic chemistry, inorganic chemistry, and crystallography with a focus on fundamental issues that are unique to materials. Primary systems of study include the chemistry of condensed phases (solids, liquids, polymers) and interfaces between different phases. Organic chemistry is the study of the structure, properties, composition, mechanisms, and reactions of organic compounds. An organic compound is defined as any compound based on a carbon skeleton.
Xi has pursued an assertive foreign policy, including toward China–United States relations, in the South China Sea, and along the Sino-Indian border dispute. He expanded China's economic and diplomatic presence in Africa and Eurasia through the Belt and Road Initiative. His 2015 meeting with Taiwanese president Ma Ying-jeou, the first between cross-strait leaders since the Chinese Civil War, was followed by deteriorating relations under the Democratic Progressive Party. He oversaw the enactment of the 2020 Hong Kong national security law, which effectively suppressed the city's pro-democracy camp. In 2018, Xi amended the constitution to remove presidential term limits and, upon his re-election in 2023, became the first Chinese president to serve more than two terms. Xi's ideology, known as Xi Jinping Thought, has been incorporated into the party and national constitutions.
==== Miniature Mass Spectrometers ==== Conventional mass spectrometers are often large as well as prohibitively expensive and complex in their operation which has led to the increased attractiveness of miniature mass spectrometers (MMS) for a variety of applications. MMS are optimized towards affordability and simple operation, often forgoing the need for experienced technicians, having a low cost of manufacture, and being small enough in size to allow for the transfer of data collection from the laboratory into the field. These advantages often come at the cost of reduced performance where MMS resolution, as well as the limits of detection and quantitation, are often barely adequate to perform specialized tasks. The integration of DMF with MMS has the potential for significant improvement of MMS systems by increasing throughput, resolution, and automation, while decreasing solvent cost, enabling lab grade analysis at a much reduced cost. In one example the use of a custom DMF system for urine drug testing enabled the creation of an instrument weighing only 25 kg with performance comparable to standard laboratory analysis.
=== Vertical transmission === In the case of some diseases such as AIDS and hepatitis B, it is possible for the offspring of infected parents to be born infected. This transmission of the disease down from the mother is referred to as vertical transmission. The influx of additional members into the infected category can be considered within the model by including a fraction of the newborn members in the infected compartment.
Epiboly is the stage of development for select organisms, such as the xenopus, sea urchin and zebrafish, when the cells of the embryo grow and migrate to the opposite end of the yolk sac to envelop it to continue developing.
Sources: en.wikipedia.org
After the Fermi publication, Otto Hahn, Lise Meitner, and Fritz Strassmann began performing similar experiments in Berlin. Meitner, an Austrian Jew, lost her Austrian citizenship with the Anschluss, the union of Austria with Germany in March 1938, but she fled in July 1938 to Sweden and started a correspondence by mail with Hahn in Berlin. By coincidence, her nephew Otto Robert Frisch, also a refugee, was also in Sweden when Meitner received a letter from Hahn dated 19 December describing his chemical proof that some of the product of the bombardment of uranium with neutrons was barium. Hahn suggested a bursting of the nucleus, but he was unsure of what the physical basis for the results were. Barium had an atomic mass 40% less than uranium, and no previously known methods of radioactive decay could account for such a large difference in the mass of the nucleus. Frisch was skeptical, but Meitner trusted Hahn's ability as a chemist. Marie Curie had been separating barium from radium for many years, and the techniques were well known. Meitner and Frisch then correctly interpreted Hahn's results to mean that the nucleus of uranium had split roughly in half. Frisch suggested the process be named "nuclear fission", by analogy to the process of living cell division into two cells, which was then called binary fission. Just as the term nuclear "chain reaction" would later be borrowed from chemistry, so the term "fission" was borrowed from biology.
==== Dopamine receptor agonists ==== Apomorphine (Apofin; CHF-1526) – non-selective dopamine receptor agonist and other actions [330] Apomorphine subcutaneous (APO-go; Apokinon; Apokyn; Apomine; Britaject; KW-6500; Li Ke Ji; Movapo; Onapgotm; SPN-830) – non-selective dopamine receptor agonist and other actions [331] Bromocriptine (Parlodel) – dopamine D2-like receptor agonist and other actions Cabergoline (Dostinex) – dopamine D2-like receptor agonist and other actions Dihydroergocryptine (DHEC; Almirid; Cripar) – dopamine D2-like receptor agonist and other actions Lisuride (Dopergin) – dopamine D2-like receptor agonist and other actions Pergolide (Permax) – dopamine D2-like receptor agonist and other actions Piribedil (Trivastal, Pronoran) – dopamine D2-like receptor agonist and other actions Pramipexole (BI-Sifrol; Daquiran; Mirapex; Mirapexin; Pexola; Sifrol; SND-919; SND-919Y) – dopamine D2, D3, and D4 receptor agonist [332] Ropinirole (Adartrel; Repreve; Requip) – dopamine D2, D3, and D4 receptor agonist [333] Ropinirole (Requip CR; Requip LP; Requip XL; Requip XR; SKF-101468A) – dopamine D2, D3, and D4 receptor agonist [334] Ropinirole transdermal (Haruropi Tape; HP-3000) – non-selective dopamine receptor agonist and other actions [335] Rotigotine transdermal (Leganto; N-0437; N-0923; Neupro; Neupro Patch; Nubrenza; SPM-962) – non-selective dopamine receptor agonist and other actions [336] Talipexole (BHT-920; Domin) – dopamine D2 receptor agonist and α2-adrenergic receptor agonist [337]
== Controversy == Though approved by the FDA in 1993, rBST has been immersed in controversy since the early 1980s. Part of the controversy concerns potential effects on animal health and human health.
Deliberative assembly shall be widely established and all matters decided by public discussion All classes, high and low, shall unite in vigorously carrying out the administration of the affairs of state The common people, no less than the civil and military of officials, shall each be allowed to pursue his own calling so that there may be no discontent. Evil customs of the past shall be broken off and everything based upon the just laws of nature. Knowledge shall be sought throughout the world so as to strengthen the foundations of imperial rule. Implicit in the Charter Oath was an end to exclusive political rule by the bakufu (a shōgun's direct administration including officers), and a move toward more democratic participation in government. To implement the Charter Oath, a rather short-lived constitution with eleven articles was drawn up in June 1868. Besides providing for a new Council of State, legislative bodies, and systems of ranks for nobles and officials, it limited office tenure to four years, allowed public balloting, provided for a new taxation system, and ordered new local administrative rules.
Sources: en.wikipedia.org
In April 1805, Britain and Russia signed a treaty with the aim of removing the French from the Batavian Republic (roughly present-day Netherlands) and the Swiss Confederation. Austria joined the alliance after the annexation of Genoa (Ligurian Republic) and the proclamation of Napoleon as King of Italy on 17 March 1805. Sweden, which had already agreed to lease Swedish Pomerania as a military base for British troops against France, entered the coalition on 9 August. The Austrians began the war by invading Bavaria on 8 September 1805 with an army of about 72,000 under Karl Mack von Leiberich, and the French army marched out from Boulogne in late July 1805 to confront them. At Ulm (25 September – 20 October) Napoleon surrounded Mack's army, forcing its surrender without significant losses. With the main Austrian army north of the Alps defeated (another army under Archduke Charles fought against André Masséna's French army in Italy), Napoleon occupied Vienna on 13 November. Far from his supply lines, he faced a larger Austro–Russian army under the command of Mikhail Kutuzov, with Emperor Alexander I of Russia personally present. On 2 December, Napoleon crushed the Austro–Russian force in Moravia at Austerlitz (usually considered his greatest victory). He inflicted 25,000 casualties on a numerically superior enemy army while sustaining fewer than 7,000 in his own force.
=== MeSH D12.644.276 – intercellular signaling peptides and proteins === MeSH D12.644.276.100 – angiogenic proteins MeSH D12.644.276.100.100 – angiopoietins MeSH D12.644.276.100.100.100 – angiopoietin-1 MeSH D12.644.276.100.100.200 – angiopoietin-2 MeSH D12.644.276.100.450 – angiostatic proteins MeSH D12.644.276.100.450.500 – angiostatins MeSH D12.644.276.100.450.750 – endostatins MeSH D12.644.276.100.800 – vascular endothelial growth factors MeSH D12.644.276.100.800.200 – vascular endothelial growth factor a MeSH D12.644.276.100.800.300 – vascular endothelial growth factor b MeSH D12.644.276.100.800.400 – vascular endothelial growth factor c MeSH D12.644.276.100.800.500 – vascular endothelial growth factor d MeSH D12.644.276.100.800.600 – vascular endothelial growth factor, endocrine-gland-derived MeSH D12.644.276.174 – cytokines MeSH D12.644.276.174.050 – autocrine motility factor MeSH D12.644.276.174.200 – chemokines MeSH D12.644.276.174.200.070 – beta-thromboglobulin MeSH D12.644.276.174.200.100 – chemokines, c MeSH D12.644.276.174.200.110 – chemokines, cc MeSH D12.644.276.174.200.120 – chemokines, cxc MeSH D12.644.276.174.200.130 – chemokines, cx3c MeSH D12.644.276.174.200.508 – interleukin-8 MeSH D12.644.276.174.200.600 – macrophage inflammatory proteins MeSH D12.644.276.174.200.600.500 – macrophage inflammatory protein-1 MeSH D12.644.276.174.200.610 – monocyte chemoattractant proteins MeSH D12.644.276.174.200.610.600 – monocyte chemoattractant protein-1 MeSH D12.644.276.174.200.700 – platelet factor 4 MeSH D12.644.276.174.200.750 – rantes MeSH D12.644.276.174.400 – growth substances MeSH D12.644.276.174.400.442 – hematopoietic cell growth factors MeSH D12.644.276.174.400.442.240 – colony-stimulating factors MeSH D12.644.276.174.400.442.240.075 – colony-stimulating factors, recombinant MeSH D12.644.276.174.400.442.240.075.350 – granulocyte colony stimulating factor, recombinant MeSH D12.644.276.174.400.442.240.075.350.275 – filgrastim MeSH D12.644.276.174.400.442.240.075.375 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.644.276.174.400.442.240.150 – erythropoietin MeSH D12.644.276.174.400.442.240.150.250 – erythropoietin, recombinant MeSH D12.644.276.174.400.442.240.150.250.250 – epoetin alfa MeSH D12.644.276.174.400.442.240.350 – granulocyte colony-stimulating factor MeSH D12.644.276.174.400.442.240.350.375 – granulocyte colony stimulating factor, recombinant MeSH D12.644.276.174.400.442.240.350.375.275 – filgrastim MeSH D12.644.276.174.400.442.240.375 – granulocyte-macrophage colony-stimulating factor MeSH D12.644.276.174.400.442.240.375.275 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.644.276.174.400.442.240.400 – interleukin-3 MeSH D12.644.276.174.400.442.240.500 – macrophage colony-stimulating factor MeSH D12.644.276.174.400.442.240.750 – thrombopoietin MeSH D12.644.276.174.400.442.800 – stem cell factor MeSH D12.644.276.174.400.505 – interleukins MeSH D12.644.276.174.400.505.501 – interleukin-1 MeSH D12.644.276.174.400.505.502 – interleukin-2 MeSH D12.644.276.174.400.505.503 – interleukin-3 MeSH D12.644.276.174.400.505.504 – interleukin-4 MeSH D12.644.276.174.400.505.505 – interleukin-5 MeSH D12.644.276.174.400.505.506 – interleukin-6 MeSH D12.644.276.174.400.505.507 – interleukin-7 MeSH D12.644.276.174.400.505.508 – interleukin-8 MeSH D12.644.276.174.400.505.509 – interleukin-9 MeSH D12.644.276.174.400.505.510 – interleukin-10 MeSH D12.644.276.174.400.505.511 – interleukin-11 MeSH D12.644.276.174.400.505.512 – interleukin-12 MeSH D12.644.276.174.400.505.513 – interleukin-13 MeSH D12.644.276.174.400.505.514 – interleukin-14 MeSH D12.644.276.174.400.505.515 – interleukin-15 MeSH D12.644.276.174.400.505.516 – interleukin-16 MeSH D12.644.276.174.400.505.517 – interleukin-17 MeSH D12.644.276.174.400.505.518 – interleukin-18 MeSH D12.644.276.174.400.800 – transforming growth factor beta MeSH D12.644.276.174.420 – hepatocyte growth factor MeSH D12.644.276.174.440 – interferons MeSH D12.644.276.174.440.890 – interferon type i MeSH D12.644.276.174.440.890.125 – interferon type i, recombinant MeSH D12.644.276.174.440.890.125.100 – interferon alfa-2a MeSH D12.644.276.174.440.890.125.150 – interferon alfa-2b MeSH D12.644.276.174.440.890.125.200 – interferon alfa-2c MeSH D12.644.276.174.440.890.250 – interferon-alpha MeSH D12.644.276.174.440.890.250.100 – interferon alfa-2a MeSH D12.644.276.174.440.890.250.150 – interferon alfa-2b MeSH D12.644.276.174.440.890.250.200 – interferon alfa-2c MeSH D12.644.276.174.440.890.275 – interferon-beta MeSH D12.644.276.174.440.893 – interferon type ii MeSH D12.644.276.174.440.893.510 – interferon-gamma, recombinant MeSH D12.644.276.174.480 – lymphokines MeSH D12.644.276.174.480.350 – interferon type ii MeSH D12.644.276.174.480.372 – interleukin-2 MeSH D12.644.276.174.480.428 – leukocyte migration-inhibitory factors MeSH D12.644.276.174.480.438 – lymphotoxin MeSH D12.644.276.174.480.615 – macrophage-activating factors MeSH D12.644.276.174.480.615.350 – interferon type ii MeSH D12.644.276.174.480.625 – macrophage migration-inhibitory factors MeSH D12.644.276.174.480.640 – neuroleukin MeSH D12.644.276.174.480.700 – suppressor factors, immunologic MeSH D12.644.276.174.480.750 – transfer factor MeSH D12.644.276.174.500 – monokines MeSH D12.644.276.174.500.400 – interleukin-1 MeSH D12.644.276.174.500.800 – tumor necrosis factor-alpha MeSH D12.644.276.174.750 – tumor necrosis factors MeSH D12.644.276.174.750.500 – lymphotoxin MeSH D12.644.276.174.750.750 – tumor necrosis factor-alpha MeSH D12.644.276.211 – endothelial growth factors MeSH D12.644.276.249 – endothelins MeSH D12.644.276.249.225 – endothelin-1 MeSH D12.644.276.249.235 – endothelin-2 MeSH D12.644.276.249.245 – endothelin-3 MeSH D12.644.276.500 – ephrins MeSH D12.644.276.500.100 – ephrin-A1 MeSH D12.644.276.500.200 – ephrin-A2 MeSH D12.644.276.500.300 – ephrin-A3 MeSH D12.644.276.500.400 – ephrin-A4 MeSH D12.644.276.500.500 – ephrin-A5 MeSH D12.644.276.500.600 – ephrin-b1 MeSH D12.644.276.500.700 – ephrin-b2 MeSH D12.644.276.500.800 – ephrin-b3 MeSH D12.644.276.625 – epidermal growth factor MeSH D12.644.276.750 – fibroblast growth factors MeSH D12.644.276.750.110 – fibroblast growth factor 1 MeSH D12.644.276.750.120 – fibroblast growth factor 2 MeSH D12.644.276.750.130 – fibroblast growth factor 3 MeSH D12.644.276.750.140 – fibroblast growth factor 4 MeSH D12.644.276.750.150 – fibroblast growth factor 5 MeSH D12.644.276.750.160 – fibroblast growth factor 6 MeSH D12.644.276.750.170 – fibroblast growth factor 7 MeSH D12.644.276.750.180 – fibroblast growth factor 8 MeSH D12.644.276.750.190 – fibroblast growth factor 9 MeSH D12.644.276.750.200 – fibroblast growth factor 10 MeSH D12.644.276.812 – i-kappa b kinase MeSH D12.644.276.875 – kinins MeSH D12.644.276.875.169 – bradykinin MeSH D12.644.276.875.169.400 – kallidin MeSH D12.644.276.875.654 – kininogens MeSH D12.644.276.875.654.350 – kininogen, high-molecular-weight MeSH D12.644.276.875.654.400 – kininogen, low-molecular-weight MeSH D12.644.276.875.900 – tachykinins MeSH D12.644.276.875.900.354 – eledoisin MeSH D12.644.276.875.900.475 – kassinin MeSH D12.644.276.875.900.500 – neurokinin a MeSH D12.644.276.875.900.550 – neurokinin b MeSH D12.644.276.875.900.800 – physalaemin MeSH D12.644.276.875.900.866 – substance p MeSH D12.644.276.937 – neuregulins MeSH D12.644.276.937.750 – neuregulin-1 MeSH D12.644.276.952 – parathyroid hormone-related protein MeSH D12.644.276.968 – platelet-derived growth factor MeSH D12.644.276.968.650 – proto-oncogene proteins c-sis MeSH D12.644.276.976 – somatomedins MeSH D12.644.276.976.400 – insulin-like growth factor i MeSH D12.644.276.976.420 – insulin-like growth factor ii MeSH D12.644.276.984 – transforming growth factors MeSH D12.644.276.984.700 – transforming growth factor alpha MeSH D12.644.276.984.720 – transforming growth factor beta MeSH D12.644.276.992 – tumor necrosis factors MeSH D12.644.276.992.500 – lymphotoxin MeSH D12.644.276.992.750 – tumor necrosis factor-alpha MeSH D12.644.276.996 – wnt proteins MeSH D12.644.276.996.500 – wnt1 protein MeSH D12.644.276.996.750 – wnt2 protein
=== Chemical diversity === As above mentioned, combinatorial chemistry was a key technology enabling the efficient generation of large screening libraries for the needs of high-throughput screening. However, now, after two decades of combinatorial chemistry, it has been pointed out that despite the increased efficiency in chemical synthesis, no increase in lead or drug candidates has been reached. This has led to analysis of chemical characteristics of combinatorial chemistry products, compared to existing drugs or natural products. The chemoinformatics concept chemical diversity, depicted as distribution of compounds in the chemical space based on their physicochemical characteristics, is often used to describe the difference between the combinatorial chemistry libraries and natural products. The synthetic, combinatorial library compounds seem to cover only a limited and quite uniform chemical space, whereas existing drugs and particularly natural products, exhibit much greater chemical diversity, distributing more evenly to the chemical space. The most prominent differences between natural products and compounds in combinatorial chemistry libraries is the number of chiral centers (much higher in natural compounds), structure rigidity (higher in natural compounds) and number of aromatic moieties (higher in combinatorial chemistry libraries).
==== Two-compartment model ==== Not all body tissues have the same blood supply, so the distribution of the drug will be slower in those tissues than in others with a better blood supply. Furthermore, there are some tissues (such as the brain tissue) that present a real barrier to the distribution of drugs, which may be breached with greater or lesser ease depending on the drug's characteristics. If these relative conditions for the different tissue types are considered along with the rate of elimination, the organism can be considered to be acting like two compartments: one that we can call the central compartment, which has a more rapid distribution and consists of organs and systems with a well-developed blood supply; and the peripheral compartment, which is made up of organs with a lower blood flow. Other tissues, such as the brain, can occupy a variable position depending on a drug's ability to passively transport (high lipophilicity) and evade active efflux to cross the blood–brain barrier (BBB) that separates the organ from the blood supply. Two-compartment models vary depending on which compartment elimination occurs in. The most common situation is that elimination occurs in the central compartment as the liver and kidneys are organs with a good blood supply. However, in some situations, elimination occurs in the peripheral compartment or even in both compartments. This can mean that there are three possible variations in the two compartment model, which still do not cover all possibilities.
Unmodified mRNA inhibits immunogenicity by triggering the production of interferons that block the generation of T helper cells, which direct B cells to produce antibodies. CureVac attempted to evade immune detection by altering the RNA sequence in a way that does not affect the coded protein, but structural differences in the non-coding regions might have affected immunogenicity. Unmodified mRNA may have decreased tolerability, leading to the adoption of a lower dose, but studies of the Pfizer–BioNTech and Moderna vaccines found only modest gains at higher doses. A next-generation vaccine from CureVac in collaboration with GlaxoSmithKline, also using unmodified mRNA, is more stable inside cells and produces higher levels of neutralizing antibodies in animals.
Sources: en.wikipedia.org
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.
Lyophilized powder is normally stored desiccated at -20 °C, protected from light and moisture. Powder kept under these conditions is generally stable for long periods. Solutions are less stable and are usually prepared immediately before use.
A purity value from one chromatographic method does not capture every possible impurity. Related peptides with similar retention behavior, counterions, and residual solvents may not appear in the same analysis. Independent testing with an orthogonal method provides stronger assurance of identity and content.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.